美国糖尿病协会(ADA)与改善全球肾脏病预后组织(KDIGO)关于糖尿病合并慢性肾脏病管理的共识报告
本共识报告由ADA与KDIGO联合工作组基于2022年ADA糖尿病诊疗标准与KDIGO 2022慢性肾脏病糖尿病管理临床实践指南制定,围绕CKD筛查与诊断、血糖监测、生活方式治疗、治疗目标及药物治疗等方面达成一致,推荐在健康生活方式基础上联用经证实可改善肾脏与心血管结局的药物治疗。
要点
- ADA与KDIGO指南在CKD筛查诊断、血糖监测、生活方式、治疗目标及药物治疗方面保持一致。
- 共识推荐在健康生活方式基础上联用经证实改善肾脏与心血管结局的药物治疗。
- 共识就RAS抑制剂、二甲双胍、SGLT2抑制剂、GLP-1受体激动剂及非甾体盐皮质激素受体拮抗剂的使用给出具体指导。
核心结论
- ADA与KDIGO联合共识为糖尿病合并CKD患者的临床管理提供明确实施方向,以改善临床结局。
研究设计与样本
- 由ADA与KDIGO代表组成的联合工作组审阅并制定系列共识声明,以指导ADA与KDIGO指南的临床实践。
主要发现
- 已发表的ADA与KDIGO指南在CKD筛查与诊断、血糖监测、生活方式治疗、治疗目标及药物治疗方面保持一致。
关键数值与推荐
- 推荐在健康生活方式基础上联用经证实可改善肾脏与心血管结局的药物治疗。
- 共识就肾素-血管紧张素系统抑制剂、二甲双胍、钠-葡萄糖协同转运蛋白2抑制剂、胰高糖素样肽-1受体激动剂及非甾体盐皮质激素受体拮抗剂的使用给出具体指导。
临床怎么用
- 共识声明为实施旨在改善糖尿病合并CKD患者临床结局的诊疗提供明确方向。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent clinical trials support new approaches to treat diabetes and CKD. The 2022 American Diabetes Association (ADA) Standards of Medical Care in Diabetes and the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease each provide evidence-based recommendations for management. A joint group of ADA and KDIGO representatives reviewed and developed a series of consensus statements to guide clinical care from the ADA and KDIGO guidelines. The published guidelines are aligned in the areas of CKD screening and diagnosis, glycemia monitoring, lifestyle therapies, treatment goals, and pharmacologic management. Recommendations include comprehensive care in which pharmacotherapy that is proven to improve kidney and cardiovascular outcomes is layered on a foundation of healthy lifestyle. Consensus statements provide specific guidance on use of renin-angiotensin system inhibitors, metformin, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist. These areas of consensus provide clear direction for implementation of care to improve clinical outcomes of people with diabetes and CKD.
引用
- de Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022. PMID: 36189689. doi:10.2337/dci22-0027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。